Patient Group Direction for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

This Patient Group Direction (PGD) is for the administration of COVID-19 mRNA vaccine BNT162b2 by the listed registered healthcare practitioners (identified in section 3) to individuals in accordance with the national COVID-19 vaccination programme.

SPS commentary:

The accompanying summary notes the PGD can be used by local organisations as the legal mechanism for administering the COVID-19 vaccine to patients and staff. It will apply from Monday 14 December 2020 to ensure there is sufficient time for organisations to update their staffing mix and delivery models.

Source:

NHS England

Resource links:

Summary